Merck KGaA Stock
€120.95
Your prediction
Merck KGaA Stock
Pros and Cons of Merck KGaA in the next few years
Pros
Cons
Performance of Merck KGaA vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Merck KGaA | 2.980% | 12.879% | 10.255% | -22.765% | -13.079% | -28.027% | -5.212% |
| Bayer AG | -0.960% | 5.549% | 2.773% | -3.316% | 48.731% | -39.998% | -36.523% |
| Elanco Animal Health Inc. | -0.500% | 4.335% | 17.512% | 33.328% | 51.316% | 38.047% | -26.083% |
| Johnson & Johnson | 1.520% | 5.015% | 5.620% | 10.666% | 15.933% | -2.562% | 29.116% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Merck (US Symbol: MKGAF) operates within the dynamic pharmaceutical industry, and its financial performance reflects a blend of growth potential and certain challenges. With a solid market capitalization of approximately €72.1 billion and a range of strategic investments, Merck exhibits an underlying strength capable of sustaining its operations and exploring future growth avenues. Analyzing the financials provides a deeper understanding of both the strengths and weaknesses that shape the company's market position.
Strong Revenue Generation
Merck's total revenue for the most recent year stands at approximately €20.82 billion. This solid revenue base underscores the company's ability to generate substantial cash flow, crucial for funding operational activities, research and development (R&D), and other strategic initiatives.
Solid Profit Margins
The profit margin is reported at 13.07%, indicating that Merck is successful in converting a significant portion of its sales into net income. This efficiency is essential in maintaining a competitive edge within an industry characterized by high research and development costs.
Comments
News
If You're In Your 20's, Consider Buying These 3 Healthcare Stocks
If you are in your 20's you likely have more than four decades ahead of you to invest before hitting retirement. Some might suggest that now is the time to take an aggressive investment stance, but
2 Magnificent Stocks to Buy That Are Near 52-Week Lows
The S&P 500 has a miserly yield of 1.2%. The average healthcare stock's yield is about 1.8%. Compared to that, Merck's (NYSE: MRK) roughly 4% yield is highly attractive. And LTC Properties' (NYSE:
3 High-Yield Healthcare Stocks to Buy Hand Over Fist in August
If you are looking at healthcare stocks for dividend ideas in August, don't get too caught up on the sector's low 1.8% dividend yield. You can do much better than that without having to take on huge